Contrasting Benitec Biopharma (NASDAQ:BNTC) and LENZ Therapeutics (NASDAQ:LENZ)

LENZ Therapeutics (NASDAQ:LENZ) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, earnings, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and target prices for LENZ Therapeutics and Benitec Biopharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	2	1	5	0	2.38
Benitec Biopharma	1	2	6	0	2.56

LENZ Therapeutics presently has a consensus target price of $29.80, suggesting a potential upside of 477.52%. Benitec Biopharma has a consensus target price of $27.00, suggesting a potential upside of 127.08%. Given LENZ Therapeutics’ higher probable upside, equities analysts plainly believe LENZ Therapeutics is more favorable than Benitec Biopharma.

Profitability

This table compares LENZ Therapeutics and Benitec Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-519.30%	-46.82%	-43.32%
Benitec Biopharma	N/A	-34.82%	-34.11%

Valuation & Earnings

This table compares LENZ Therapeutics and Benitec Biopharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09 million	8.47	-$82.13 million	($3.60)	-1.43
Benitec Biopharma	N/A	N/A	-$37.92 million	($1.14)	-10.43

Benitec Biopharma has lower revenue, but higher earnings than LENZ Therapeutics. Benitec Biopharma is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by insiders. Comparatively, 4.8% of Benitec Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

LENZ Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500.

Summary

Benitec Biopharma beats LENZ Therapeutics on 7 of the 13 factors compared between the two stocks.

About LENZ Therapeutics

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

About Benitec Biopharma

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.